Orchid Pharma announced the launch of its new drug - Cefepime-Enmetazobactam, which has been approved for the treatment of complicated Urinary Tract infections (cUTI), Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) indications.

In a landmark collaboration, Orchid Pharma has partnered with Cipla to ensure widespread and rapid distribution of this breakthrough antibiotic combination across India.